Organon & Co. filings document the regulatory record for a NYSE-listed global healthcare company with Women's Health and General Medicines portfolios, including biosimilars. Form 8-K reports cover operating and financial results, company presentations, clinical or regulatory disclosures, material agreements, and other material events tied to the healthcare portfolio.
Proxy and governance filings describe board composition, executive compensation, shareholder voting matters, equity-award disclosures, and common stock registered under the Exchange Act. The filing record also includes disclosures on board and committee changes, audit committee review matters, capital structure, and exhibits filed in Inline XBRL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
FAQ
How many ORGANON & CO (OGN) SEC filings are available on StockTitan?
StockTitan tracks 63 SEC filings for ORGANON & CO (OGN), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for ORGANON & CO (OGN)?
The most recent SEC filing for ORGANON & CO (OGN) was filed on August 5, 2025.